Navigation Links
China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
Date:5/4/2009

HARBIN, China, May 4 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Research & Development project for the Company's Sudden Cardiac Death (SCD) Early Examination Kit has been appraised by the Heilongjiang Bureau of Science and Technology. The R&D project was undertaken jointly by China Sky One Medical and Harbin Medical University.

The leader of this project is Prof. Baofeng Yang, the Principal of Harbin Medical University, who is also the Chief Scientist of Chinese National 973 Project and Standing Director of the China Pharmaceutical Alliance. Prof. Yang has dedicated a large part of his career to researching SCD and his fundamental research has led to several breakthroughs. In 2008, Prof. Yang and his research team found that the concentration of a substance called "MicroRNA-1" in human blood has positive correlation with the occurrence of SCD. After detailed clinical studies involving many samples, Prof. Yang concluded that the existence of MicroRNA-1 in human blood is a useful predictor of SCD, and higher concentrations of MicroRNA-1 means a higher probability of SCD. The discovery was published in the Journal of Nature-Medicine. In late 2008, Prof. Yang received the national patent for this discovery.

In order to commercialize SCD diagnostic technology, Harbin Medical University transferred the patent exclusively to Harbin First Bio-Engineering Company Limited, the wholly owned subsidiary of China Sky One Medical, in early 2009. The two parties will collaborate in researching a production method for the SCD Early Examination Kit that includes large scale clinical trial comparisons. Their research has been going smoothly and according to schedule.

The team of specialists from the Heilongjiang Bureau of Science and Technology concluded that the research was successful and reliably conducted. As a result, the Company is permitted to begin the research and application process for its Sudden Cardiac Death (SCD) Early Examination Kit, which will be classified as a national new product under the diagnostic kit category. The appraisal team noted that the success of the project would represent a significant breakthrough in preventing and reducing the threat of SCD.

"We are proud because this project represents one of the very few proprietary technologies in the bio-diagnostic field that is owned by the Chinese," Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We expect to complete the new product application process within one year. We believe that there is huge market potential for this new product and that revenues could likely reach over $20 million a year."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com.

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    Company Contact:                        Investor Relations Contact:
    China Sky One Medical, Inc.             CCG Investor Relations
    Mr. Yu-Bo Hao, CFO                      Mr. Crocker Coulson, President
    Tel: +86-0451-53994069                  Tel: +1-646-213-1915
    Email: china_sky_one@yahoo.cn           Email: crocker.coulson@ccgir.com
                                                  Website: www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
2. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
3. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
6. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
7. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
8. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
9. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
10. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
11. Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... -- Vestagen Technical Textiles, Inc., a medical technology company ... other demanding applications, today announced it has named ... Dale Pfost , PhD, who was serving as interim ... Vestagen,s Board of Directors. ® , the ... that combines fluid repellent, antimicrobial and breathability properties. VESTEX ...
(Date:2/8/2016)... Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... injectable drug delivery systems, today announced that it will release ... December 31, 2015 after market close on February 9, 2016. ... call to discuss these financial results.    About ... --> About Unilife Corporation ...
(Date:2/8/2016)...  Astellas Pharma Inc. President and Chief Executive Officer ... Robinson as president, Americas Operations, for Astellas US LLC, ... South America , effective April 1, 2016.  Robinson ... organization in the United States -- ... Yoshida , who is retiring in June 2016.  ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving ... program, has teamed up with Citizens Opposed to Domestic Abuse in support of its ... support all those victimized by the fear of violence in their own homes, donations ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... enrichment program serving the greater Venice, FL area, has initiated a fundraiser for ... a car accident just four days after Christmas. To support this beautiful child ...
(Date:2/8/2016)... ... February 08, 2016 , ... T.E.N., ... that nominations will be accepted February 8, 2016 through May 8, 2016 ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... frequently. While a significant number of women and men with eating disorders report ... itself, that best predicts the development of an eating disorder. , At ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Discover the ... visit over 1,400 booths and 700 companies. Attendees also get to see the ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 ...
Breaking Medicine News(10 mins):